ClinicalTrials.gg
CompletedNCT05627518BAUpdated Apr 3, 2025Results posted

Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

A Phase 1 interventional study of Linaprazan glurate in Safety, Bioavailability and Pharmacokinetics, sponsored by Cinclus Pharma Holding AB. Completed at 1 site in Slovenia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Cinclus Pharma Holding AB · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single-center, open-label, randomized, single dose, 3-way crossover study in healthy volunteers designed to evaluate the relative bioavailability of a new oral tablet formulation of linaprazan glurate in comparison to a previously studied oral tablet formulation under fasting conditions, and to assess the effect of a high fat, high calorie meal on the pharmacokinetics (PK) of linaprazan glurate and the active substance linaprazan after the administration of the new oral tablet formulation.

02

Conditions studied

  • Safety
  • Bioavailability
  • Pharmacokinetics
03

In context

Lead sponsor

Cinclus Pharma Holding AB is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. Willing and able to give written for participation in the study.
  2. Healthy male or female aged 18 to 65 years, inclusive.
  3. ≥18.5 and ≤30.0 kg/m2.
  4. Medically healthy, without abnormal medical history
  5. Female subjects of , as well as their partners and male subjects and their partners, who agree to using methods of
  6. Willing and able to consume the high-fat, high calorie breakfast

Exclusion Criteria:

  1. Female subjects of childbearing potential unless they agree to use highly effective methods of contraception (failure rate of \<1%) from 2 weeks prior to dosing until the end-of-study visit.
  2. Male subjects with a partner of childbearing potential, unless they agree to use method of contraception from 2 weeks prior to dosing until the end-of-study visit.History of or current clinically significant disease as defined in the protocol
  3. History of or current clinically significant disease as defined in the protocol.
  4. History of GERD, significant acid reflux.
  5. Subjects who are pregnant, currently breastfeeding, or intend to become pregnant (female subjects) or father a child (male subjects) during the course of the study (i.e., from screening to end of study visit).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    Reference formulation (Treatment A)

    100 mg linaprazan glurate reference formulation (4x25 mg oral tablets) in fasting conditions

    Drug: Linaprazan glurate

  • Experimental
    Test formulation (Treatment B)

    100 mg linaprazan glurate test formulation (1x100 mg oral tablet) in fasting conditions

    Drug: Linaprazan glurate

  • Experimental
    Test Formulation (Treatment C)

    100 mg linaprazan glurate test formulation (1x100 mg oral tablet) in fed conditions

    Drug: Linaprazan glurate

Interventions

06

What researchers measure

Primary outcomes

  1. Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratios of AUCinf and AUClast

    The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.

    Time frame: From pre-dose up to 72 h post dose

  2. Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax

    The Ratio of Cmax (highest measured concentration) of linaprazan comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.

    Time frame: From pre-dose up to 72 h post dose

  3. Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf and AUClast

    The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased in a fed vs fasted state.

    Time frame: From pre-dose up to 72 h post dose

  4. Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for Cmax

    The Ratio of Cmax of linaprazan when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan exposure is increased or decreased with the new formulation.

    Time frame: From pre-dose up to 72 h post dose

Secondary outcomes

  1. Relative Bioavailability of Linaprazan Glurate for the Test Formulation vs. Reference Formulation of Linaprazan Glurate, Based on the Means Ratios of PK Parameters.

    The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprzan glurate, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.

    Time frame: From pre-dose up to 72 h post dose

  2. Relative Bioavailability of Linaprazan Glurate Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax

    The Ratio of Cmax (highest measured concentration) of linaprazan glurate comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.

    Time frame: From pre-dose up to 72 h post dose

  3. Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf, AUClast

    The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan glurate, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased in a fed vs fasted state.

    Time frame: From pre-dose up to 72 h post dose

  4. Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratio of Cmax

    The Ratio of Cmax of linaprazan glurate when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.

    Time frame: From pre-dose up to 72 h post dose

07

Results

Posted Apr 3, 2025

Participant flow

Subjects were recruited form CRS's database of healthy volunteers. All Volunteers were recruited in Slovenia, Ljubljana.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTreatment Sequence A B CTreatment Sequence A C BTreatment Sequence B A CTreatment Sequence B C ATreatment Sequence C A BTreatment Sequence C B AExploratory Arm A B CExploratory Arm A C B
Started99999967
Completed99799800
Not completed00200167
Withdrew: Adverse event00100001
Withdrew: Withdrawal by subject00100100
Withdrew: Protocol violation00000066
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTreatment Sequence A B CTreatment Sequence A C BTreatment Sequence B A CTreatment Sequence B C ATreatment Sequence C A BTreatment Sequence C B AExploratory Arm A B CExploratory Arm A C B
Started99799800
Completed79799800
Not completed20000000
Withdrew: Adverse event10000000
Withdrew: Withdrawal by subject10000000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneTreatment Sequence A B CTreatment Sequence A C BTreatment Sequence B A CTreatment Sequence B C ATreatment Sequence C A BTreatment Sequence C B AExploratory Arm A B CExploratory Arm A C B
Started79799800
Completed79799800
Not completed00000000

Outcome measures

PrimaryRelative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratios of AUCinf and AUClast

The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · hours * nmol/Liter
Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratios of AUCinf and AUClast
hours * nmol/LiterReference Formulation (Treatment A)Test Formulation (Treatment B)
AUCinf12341 ± 1.5125001 ± 1.32
AUClast10016.2 ± 2.7824175.8 ± 1.34
Statistical analysis
  • Reference Formulation (Treatment A) vs Test Formulation (Treatment B) · Mixed Models Analysis · p = <0.0001 · Ratio: 1.9954 · 95% CI 1.8399 to 2.1641Treatment B (1x100 mg test formulation) divided by treatment A (4x25 mg reference formulation)
  • Reference Formulation (Treatment A) vs Test Formulation (Treatment B) · Mixed Models Analysis · p = <0.0001 · Ratio: 2.1250 · 95% CI 1.9664 to 2.2963Treatment B (1x100 mg test formulation) divided by treatment A (4x25 mg reference formulation)
PrimaryRelative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax

The Ratio of Cmax (highest measured concentration) of linaprazan comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · nmol/L
Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax
nmol/LReference Formulation (Treatment A)Test Formulation (Treatment B)
Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax1430 ± 1.833462.2 ± 1.25
Statistical analysis
  • Reference Formulation (Treatment A) vs Test Formulation (Treatment B) · Mixed Models Analysis · p = <0.0001 · Ratio: 2.3167 · 95% CI 2.0922 to 2.5652Treatment B (1x100 mg test formulation) divided by treatment A (4x25 mg reference formulation)
PrimaryRelative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf and AUClast

The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased in a fed vs fasted state.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · hours * nmol/Liter
Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf and AUClast
hours * nmol/LiterTest Formulation (Treatment B)Test Formulation (Treatment C)
AUCinf25001 ± 1.3219448.9 ± 1.32
AUClast24175.8 ± 1.3419022.8 ± 1.32
Statistical analysis
  • Test Formulation (Treatment B) vs Test Formulation (Treatment C) · Mixed Models Analysis · p = <0.0001 · Ratio: 0.7570 · 95% CI 0.7009 to 0.8177Treatment C (1x100 mg test formulation fed) divided by treament B (100 mg test formulation fasted)
  • Test Formulation (Treatment B) vs Test Formulation (Treatment C) · Mixed Models Analysis · p = <0.0001 · Ratio: 0.7684 · 95% CI 0.7102 to 0.8313Treatment C (1x100 mg test formulation fed) divided by treament B (100 mg test formulation fasted)
PrimaryRelative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for Cmax

The Ratio of Cmax of linaprazan when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan exposure is increased or decreased with the new formulation.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · nmol/L
Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for Cmax
nmol/LTest Formulation (Treatment B)Test Formulation (Treatment C)
Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for Cmax3462.2 ± 1.251608 ± 1.29
Statistical analysis
  • Test Formulation (Treatment B) vs Test Formulation (Treatment C) · Mixed Models Analysis · p = <0.0001 · Ratio: 0.2548 · 95% CI 0.1999 to 0.3247Treatment C (1x100 mg test formulation fed) divided by treament B (100 mg test formulation fasted)
SecondaryRelative Bioavailability of Linaprazan Glurate for the Test Formulation vs. Reference Formulation of Linaprazan Glurate, Based on the Means Ratios of PK Parameters.

The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprzan glurate, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · hours * nmol/Liter
Relative Bioavailability of Linaprazan Glurate for the Test Formulation vs. Reference Formulation of Linaprazan Glurate, Based on the Means Ratios of PK Parameters.
hours * nmol/LiterReference Formulation (Treatment A)Test Formulation (Treatment B)
AUCinf114.2 ± 1.95320.2 ± 1.73
AUClast83.9 ± 2.49293 ± 1.84
Statistical analysis
  • Reference Formulation (Treatment A) vs Test Formulation (Treatment B) · Mixed Models Analysis · p = <0.0001 · Ratio: 3.0245 · 95% CI 2.5098 to 3.6446Treatment B (1x100 mg test formulation) divided by treament A (4x25 mg reference formulation)
  • Reference Formulation (Treatment A) vs Test Formulation (Treatment B) · Mixed Models Analysis · p = <0.0001 · Ratio: 3.5277 · 95% CI 2.9076 to 4.2799Treatment B (1x100 mg test formulation) divided by treament A (4x25 mg reference formulation)
SecondaryRelative Bioavailability of Linaprazan Glurate Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax

The Ratio of Cmax (highest measured concentration) of linaprazan glurate comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · nmol/L
Relative Bioavailability of Linaprazan Glurate Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax
nmol/LReference Formulation (Treatment A)Test Formulation (Treatment B)
Relative Bioavailability of Linaprazan Glurate Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax86.8 ± 2.44214.3 ± 2.08
Statistical analysis
  • Reference Formulation (Treatment A) vs Test Formulation (Treatment B) · Mixed Models Analysis · p = <0.0001 · Ratio: 3.0245 · 95% CI 2.5098 to 3.6446Treatment B (1x100 mg test formulation) divided by treament A (4x25 mg reference formulation)
SecondaryRelative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf, AUClast

The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan glurate, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased in a fed vs fasted state.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · hours * nmol/Liter
Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf, AUClast
hours * nmol/LiterTest Formulation (Treatment B)Test Formulation (Treatment C)
AUCinf320.2 ± 1.73166.3 ± 1.52
AUClast293.0 ± 1.84144.3 ± 1.62
Statistical analysis
  • Test Formulation (Treatment B) vs Test Formulation (Treatment C) · Mixed Models Analysis · p = <0.0001 · Ratio: 0.4923 · 95% CI 0.4131 to 0.5867Treatment C (1x100 mg test formulation fed) divided by treament B (100 mg test formulation fasted)
  • Test Formulation (Treatment B) vs Test Formulation (Treatment C) · Mixed Models Analysis · p = <0.0001 · Ratio: 0.4923 · 95% CI 0.4047 to 0.5989Treatment C (1x100 mg test formulation fed) divided by treament B (100 mg test formulation fasted)
SecondaryRelative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratio of Cmax

The Ratio of Cmax of linaprazan glurate when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.

Time frame:
From pre-dose up to 72 h post dose
Reported as:
Geometric mean · nmol/L
Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratio of Cmax
nmol/LTest Formulation (Treatment B)Test Formulation (Treatment C)
Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratio of Cmax214.3 ± 2.0855.0 ± 2.23
Statistical analysis
  • Test Formulation (Treatment B) vs Test Formulation (Treatment C) · Mixed Models Analysis · p = <0.0001 · Ratio: 0.2522 · 95% CI 0.1980 to 0.3211Treatment C (1x100 mg test formulation fed) divided by treament B (100 mg test formulation fasted)

Adverse events

Collected over Baseline to Visit 5, 1 month. Non-serious events are listed at a 1.40% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference Formulation (Treatment A)0/51 (0%)0/51 (0%)17/51 (33.3%)
Test Formulation (Treatment B)0/53 (0%)1/53 (1.9%)12/53 (22.6%)
Test Formulation (Treatment C)0/50 (0%)0/50 (0%)14/50 (28%)
Reference0/13 (0%)0/13 (0%)4/13 (30.8%)
Most frequent serious events
Most frequent serious events
EventReference Formulation (Treatment A)Test Formulation (Treatment B)Test Formulation (Treatment C)Reference
Skin Bacterial InfectionSkin and subcutaneous tissue disorders0/511/530/500/13
Most frequent other events
Showing 10 of 16
Most frequent other events
EventReference Formulation (Treatment A)Test Formulation (Treatment B)Test Formulation (Treatment C)Reference
PapulaSkin and subcutaneous tissue disorders0/510/530/502/13
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders1/510/530/502/13
NasopharyngitisInfections and infestations3/510/534/500/13
Cardiac disordersCardiac disorders4/513/531/500/13
Vascular disordersSkin and subcutaneous tissue disorders1/512/533/500/13
TachycardiaCardiac disorders3/513/531/500/13
HeadacheNervous system disorders3/511/532/500/13
PhlebitisVascular disorders0/511/532/500/13
DiarrhoeaGastrointestinal disorders2/510/530/500/13
VomitingGastrointestinal disorders2/510/530/500/13

Baseline characteristics

13 subjects were erroneously underdosed with 1x25 mg LG instead of 4x25 mg in the sequence arms starting with treatment A. These 13 subjects were excluded from the analysis set and replaced. Data was collected nevertheless and presented as "exploratory". This is why there is an imbalance between the number in the first two sequence arms. In addition, in error, one subject recieved the treatments in reverse order from his/her randomization. E.g. B C A instead of as randomized to A C B.

Age, Categorical
Age, Categorical(Participants)Treatment Sequence A B CTreatment A C BTreatment B A CTreatment B C ATreatment C A BTreatment C B ATotal
<=18 years0000000
Between 18 and 65 years15159109967
>=65 years0000000
Age, Continuous
Age, Continuous(years)Treatment Sequence A B CTreatment A C BTreatment B A CTreatment B C ATreatment C A BTreatment C B ATotal
Mean22.2 (19 to 26)24.3 (18 to 35)26.4 (19 to 45)21.5 (18 to 25)29.6 (19 to 48)22.3 (19 to 26)24.1 (18 to 48)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence A B CTreatment A C BTreatment B A CTreatment B C ATreatment C A BTreatment C B ATotal
Female79826335
Male86183632
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence A B CTreatment A C BTreatment B A CTreatment B C ATreatment C A BTreatment C B ATotal
Hispanic or Latino1000001
Not Hispanic or Latino14159109966
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Treatment Sequence A B CTreatment A C BTreatment B A CTreatment B C ATreatment C A BTreatment C B ATotal
Slovenia15159109967
08

Study locations

1 site
  • CRS d.o.o.
    Ljubljana, Ukmarjeva Ulica 6 1000, Slovenia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Dec 2022, 1 month.

Results were first posted in Apr 2025, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Nov 25, 2022
StartActual
Nov 15, 2022
Primary completionActual
Dec 30, 2022
CompletionActual
Jan 3, 2023
Results first posted
Apr 3, 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05627518
Lead sponsor
Cinclus Pharma Holding AB
Responsible party
Sponsor
First posted
Nov 25, 2022
Start date
Nov 15, 2022
Primary completion
Dec 30, 2022
Completion
Jan 3, 2023
Results posted
Apr 3, 2025
Last update
Apr 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linaprazan glurate

Start the discussion